0      0

AONN+ Annual 2020

FRI06 - Industry Sponsored Session | Reduce the Risk of Recurrence in HER2+ Breast Cancer: Proactive Treatment Management Strategies (non-CE) Presentation by Puma Biotechnology

Nov 6, 2020 12:15pm ‐ Nov 6, 2020 1:30pm


Please join us for this educational program on Friday, November 6th at 12:15 PM EST to learn more about NERLYNX® (neratinib) for HER2+ Breast Cancer including how to anticipate and mitigate TKI adverse events. Anne Sosna RN, BSN from Puma Biotechnology will share data on NERLYNX and strategies to equip you and your practice to support these high-risk patients on TKI therapy. Valarie, a NERLYNX Patient, will also share her experience and will be available for questions.


  • Anne Sosna, RN, BSN, Clinical Nurse Educator, Puma Biotechnology

You must be logged in and own this session in order to post comments.